

Factors Associated With Revision Surgery After Internal Fixation of Hip Fractures

Sheila Sprague, PhD, Emil H. Schemitsch, MD, FRCSC, Marc Swiontkowski, MD, Gregory J. Della Rocca, MD, PhD, FACS, Kyle J. Jeray, MD, Susan Liew, MBBS, Gerard P. Slobogean, MD, MPH, Sofia Bzovsky, BSc, Diane Heels-Ansdell, MSc, Qi Zhou, PhD, and Mohit Bhandari, MD, PhD, FRCSC on behalf of the FAITH Investigators

Abstract

Background: Femoral neck fractures are associated with high rates of revision surgery after management with internal fixation. Using data from the Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) trial evaluating methods of internal fixation in patients with femoral neck fractures, we investigated associations between baseline and surgical factors and the need for revision surgery to promote healing, relieve pain, treat infection or improve function over 24 months postsurgery. Additionally, we investigated factors associated with (1) hardware removal and (2) implant exchange from cancellous screws (CS) or sliding hip screw (SHS) to total hip arthroplasty, hemiarthroplasty, or another internal fixation device.

Methods: We identified 15 potential factors a priori that may be associated with revision surgery, 7 with hardware removal, and 14 with implant exchange. We used multivariable Cox proportional hazards analyses in our investigation.

Results: Factors associated with increased risk of revision surgery included: female sex, [hazard ratio (HR) 1.79, 95% confidence interval (CI) 1.25–2.50; $P = 0.001$], higher body mass index (for every 5-point increase) (HR 1.19, 95% CI 1.02–1.39; $P = 0.027$), displaced fracture (HR 2.16, 95% CI 1.44–3.23; $P = 0.001$), unacceptable quality of implant placement (HR 2.70, 95% CI 1.59–4.55; $P = 0.001$), and smokers treated with cancellous screws versus smokers treated with a

sliding hip screw (HR 2.94, 95% CI 1.35–6.25; P = 0.006). Additionally, for every 10-year decrease in age, participants experienced an average increased risk of 39% for hardware removal.

Conclusions: Results of this study may inform future research by identifying high-risk patients who may be better treated with arthroplasty and may benefit from adjuncts to care (HR 1.39, 95% CI 1.05–1.85; P = 0.020).

Introduction

Hip fractures in elderly adults are common, affecting approximately 1.6 million individuals worldwide each year and resulting in a significant amount of morbidity and mortality.^{1,2} Fractures of the femoral neck generally necessitate surgical management with either internal fixation or arthroplasty and there exists controversy surrounding which of these 2 treatment options is optimal in elderly patients.³ Typically, most displaced fractures of the femoral neck are treated with arthroplasty, but there exists evidence to suggest that internal fixation is better suited for treating undisplaced fractures.⁴ In addition, internal fixation does offer some advantages over arthroplasty, including less surgical trauma, allowing the patient to retain their own femoral head, and a marginal reduction in mortality and morbidity in very frail patients.⁵ Regardless of treatment option, fractures of the femoral neck are associated with high rates of complications, including nonunion, delayed union, shortening, infection, and avascular necrosis.³ Our recently completed Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) trial found a high revision surgery rate of 20.8%, which was actually lower than a previously conducted meta-analysis.⁶ Revision surgery prolongs patients' recovery time, is associated with higher rates of complications, and reduces patients' health-related quality of life. Identifying factors that are associated with revision surgery, and precisely which type of revision surgery, can

aid surgeons in making treatment decisions and optimizing the care of hip fracture patients.

The recently completed FAITH randomized controlled trial evaluated the effectiveness of internal fixation with a sliding hip screw (SHS) versus cancellous screws (CS) in patients with a femoral neck fracture.⁷ The primary outcome of this trial was the rate of revision surgery to promote fracture healing, relieve pain, treat infection, or improve function within 24 months of fracture.⁷ Our primary aim was to identify factors associated with an increased risk of revision surgery, as defined above, for patients enrolled in the FAITH trial. Our secondary aims were to determine factors associated with an increased risk of surgery for hardware removal, defined as the removal of CS or SHS, and surgery for implant exchange, defined as the conversion of CS or SHS to total hip arthroplasty (THA), hemiarthroplasty (HA), or another internal fixation device.

Materials and Methods

FAITH Study Overview

The FAITH trial (Clinical Trials Identification Number: NCT00761813) enrolled 1079 patients with a low-energy femoral neck fracture requiring fracture fixation from 81 clinical sites in the United States, Canada, Australia, the Netherlands, Norway, Germany, the United Kingdom, and India. Patients were assessed clinically at 1 and 10 weeks and 6, 9, 12, 18, and 24-months postsurgery. The primary outcome of the FAITH trial was revision surgery to promote healing, relieve pain, treat infection, or improve function over 24-months postsurgery.^{7,8} All revision surgeries were reviewed by a Central Adjudication Committee. The trial protocol and results have been previously published.^{7,8} The trial was approved by the Hamilton Integrated Research Ethics Board (#06-402) and by all

participating clinical sites' Research Ethics Boards/Institutional Review Boards.

Selection of Factors

Based on biologic rationale and previous literature,⁹ a priori we identified 22 potential factors that may be associated with revision surgery, from the baseline data, fracture characteristics, and surgical data collected as part of the FAITH trial (Table 1).⁷ When selecting factors for each analysis, we ensured that there were at least 10 events for each factor to avoid having an overfitted or unstable model.¹⁰ Of note, we had intended to include quality of reduction within the models; however, less than 10 patients had unacceptable quality of reduction. Therefore, this factor was not included in the models. The number of factors included was based on the primary outcome of the FAITH trial, revision surgery. As 224 participants had a revision surgery to promote healing, relieve pain, treat infection or improve function over 24-months post-surgery, all 22 preidentified factors (including levels) could be used in our analysis. We included 15 factors with 22 levels (Table 1) in our analysis. Because logistic and Cox models require at least 10 events per covariate to produce stable estimates,¹⁰ the minimum number participants required to support the analysis of 22 factors would be 220 participants. As 74 participants underwent hardware removal surgery, we selected 7 factors that might be associated with hardware removal in our model (Table 2). Finally, 150 participants had implant exchange surgery. Therefore, we selected 14 factors to be included in this model (Table 3). For every factor in each of our 3 models, we proposed a priori a hypothesized effect and rationale for revision surgery, hardware removal, and implant exchange, respectively.

Data Analysis

We used multivariable Cox proportional hazards regression stratified by center

analyses to investigate the association between our selected factors and increased risk of revision surgery, hardware removal, and implant exchange. An interaction term between the randomized treatment and smoking status was added to all models because this interaction was found to be significant in the FAITH primary paper.⁷ All FAITH patients with complete data for all selected factors were included in the analysis. Results were reported as adjusted hazard ratios (HR), 95% confidence intervals (CIs), and associated P-values. All tests were 2-tailed with alpha = 0.05. We tested the assumption of proportional hazards for all independent variables. We performed all analyses using SAS software (version 9.4; SAS Institute, Cary, NC).

Results

Participant Characteristics

Eight hundred fifteen patients enrolled in the FAITH trial had complete prognostic and follow-up data for the 15 selected factors and were included in the revision surgery model (mean age: 73.4 years; 64% female). Complete data were available for 894 (mean age: 73.4 years; 64% female) and 823 (mean age: 73.6 years; 64% female) patients to perform the analyses investigating factors associated with hardware removal and implant exchange, respectively. Of the patients included in this analysis, 191 patients had revision surgeries to promote fracture healing, relieve pain, treat infection, or improve function. Within this subset, there were 70 hardware removal surgeries and 143 implant exchange surgeries (92 conversions to THA, 44 conversions to HA, and 9 IF exchanges).

Factors Associated With Revision Surgery

Female sex (HR 1.79, 95% CI 1.25–2.50; P = 0.001), displaced fracture (HR 2.16,

95% CI 1.44–3.23; $P = 0.001$), and a fracture configuration corresponding to a Pauwels type III as compared to type II (HR 2.13, 95% CI 1.28–3.57; $P = 0.004$) were associated with a higher risk of revision surgery (Table 1). Unacceptable quality of implant placement, which was adjudicated by the Central Adjudication Committee and was defined in the FAITH trial as evidence of prominent screws (at the lateral femoral cortex), screw penetration, and lag screw being too high on immediate post-operative radiographs, was also found to be associated with a higher risk of revision surgery (HR 2.70, 95% CI 1.59–4.55; $P = 0.001$). Lastly, we found that for every 5-point increase in body mass index (BMI), participants experienced an average increased risk of 19% for revision surgery (HR 1.19, 95% CI 1.02–1.39; $P = 0.027$) during the 24-month follow-up period. Additionally, we found that being treated with CS (compared to SHS) increased the risk of revision surgery in patients who were smokers (HR 2.94, 95% CI 1.35–6.25; $P = 0.006$). No other factors were significantly associated with revision surgery ($P > 0.05$).

Factors Associated With Hardware Removal

Having a displaced fracture (HR 2.91, 95% CI 1.63–5.18; $P = 0.001$) and unacceptable quality of implant placement (HR 2.56, 95% CI 1.11–5.88; $P = 0.027$) were associated with an increased risk of hardware removal (Table 2). We found that for every 10-year decrease in age, participants experienced an average increased risk of 39% for hardware removal (HR 1.39, 95% CI 1.05–1.85; $P = 0.020$) during the 24-month follow-up period. Additionally, we found that being treated with CS compared to a SHS was associated with an increased risk of hardware removal; however, the treatment effect was significantly higher in non-smokers/prior smokers (HR 0.53, 95% CI 0.29–0.96; $P = 0.040$) compared to current smokers (HR 0.09, 95% CI 0.02–0.37; $P = 0.001$). BMI and prefracture functional status were not associated with hardware removal ($P > 0.05$).

Factors Associated With Implant Exchange

Factors associated with an increased risk of implant exchange included: female sex (HR 2.00, 95% CI 1.32–3.03; $P = 0.001$), displaced fracture (HR 2.31, 95% CI 1.45–3.69; $P 0.001$), and unacceptable quality of implant placement (HR 2.38, 95% CI 1.32–4.35; $P , 0.001$) (Table 3). No other factors were significantly associated with implant exchange ($P < 0.05$).

Discussion

Using data from the FAITH trial, we investigated factors associated with revision surgery, hardware removal, and implant exchange in patients over the age of 50 with a low-energy femoral neck fracture.⁷ To date, there have been a limited number of studies that have enrolled large numbers of femoral neck fracture patients treated with internal fixation across multiple centers and countries. Assessing nearly 1000 participants provided us with greater precision in our secondary analyses for determining the factors associated with overall revision surgery, hardware removal, and implant exchange surgery.

In the FAITH primary paper, the interaction between randomized treatment and smoking status was found to be statistically significant. When this interaction term was added to the overall revision surgery model and the hardware removal model, a SHS was found to be beneficial in smokers (compared to CS). The existing literature concerning the risk of revision surgery in smokers following internal fixation of a femoral neck fracture is currently lacking. At this time, only one other published study has evaluated factors associated with revision surgery for femoral neck fractures, but this study did not assess whether smoking was a factor.⁹ However, there is fracture healing literature that suggests that smoking can have a negative effect on bone healing.^{11–14} One systematic review containing 9 tibia

studies and 8 other orthopaedic studies found that, overall, smoking had a negative effect on bone healing, in terms of delayed union, non-union, and other complications.¹¹ Another systematic review found similar findings that smoking significantly increased the risk of nonunion of fractures overall [odds ratio (OR) 2.32; 95% CI 1.76–3.06; P, 0.001], tibial fractures (OR 2.16; 95% CI 1.55–3.01; P < 0.001), and open fractures (OR 1.95; 95% CI 1.3–2.9; P, 0.001).¹²

Additionally, a recently published prospective, multicentre, cohort study evaluating the treatment of acute tibial plateau fractures with open reduction and internal fixation found that current smoking was an independent risk factor for the development of surgical site infection (OR 5.68; 95% CI 1.56–20.66; P = 0.009).¹³ Smoking is also known to have a negative impact on bone density that impacts post-surgical fracture mechanical stability.¹⁵ Our finding that smokers receiving a SHS will have better outcomes needs to be confirmed through future research conducted on this topic.

Patients with a type III Pauwels fracture compared to type II were found to be at a significantly higher risk of revision surgery in the current study. However, those with a type III Pauwels fracture were not found to be at a higher risk of revision surgery compared to patients with a type I Pauwels fracture. This may have been due to a smaller proportion of patients with fractures classified as type I (n = 93) or type III (n = 107) compared to type II (n = 615). Although some evidence suggests that Pauwels classification may not be highly reliable, it is still widely used to classify femoral neck fractures.¹⁶

The Gregersen et al⁹ trial found that underweight elderly individuals (BMI < 19) had a lower risk of revision surgery compared to elderly individuals with a BMI ≥ 19 (HR 0.33, 95% CI 0.11–0.95; P = 0.040). This finding was similar to ours and may result from the increased amount of stress on the implant. Additionally, the Gregersen et al⁹ trial found that a higher risk of revision surgery was associated

with living at home independently compared to living in a nursing home (HR 2.67; 95% CI 1.35–5.31; $P = 0.005$) and with poor quality of fracture reduction in displaced fractures (HR 1.95; 95% CI: 1.02–3.72; $P = 0.040$). Gregersen et al defined poor reduction as fracture displacement greater than 5 mm, an anteroposterior Garden angle outside the interval of 160–175 degrees, or a posterior or anterior angulation greater than 20 degrees.^{9,17} This finding was consistent with an earlier study which found that poor reduction led to a higher risk of treatment failure following internal fixation of displaced fractures of the femoral neck.¹⁸ Due to a low number of participants with an unacceptable reduction, we did not include this factor in our models. Review of the quality of fracture reduction by a Central Adjudication Committee in the FAITH trial found that only 5 participants had unacceptable reduction. Radiographs of the hip fracture were examined by the Central Adjudication Committee for approximation of the displaced fracture fragments and overall fracture alignment. The Adjudication Committee assessed the quality of reduction. Although there are radiologic predictors of failure, the absolute cutoffs for acceptable and unacceptable reductions are not known. Therefore, the Central Adjudication Committee erred on the side of acceptable, except in cases where there was gross malreduction, which rarely occurred.

To ensure that all conversion surgeries were captured, our implant exchange model included conversion to THA, HA, or another internal fixation device.¹⁹ Arthroplasty involves partial or full replacement of a joint, whereas internal fixation involves joint preservation. Therefore, the two procedures are very different clinically. For this reason, we repeated the implant exchange analysis removing the 9 patients who underwent implant exchange to another internal fixation device. Typically, implant exchanges mostly involve THA and HA procedures, whereas implant exchanges to another internal fixation device are less

common. We found similar results to our original analysis where female sex ($P = 0.001$), displaced fracture ($P = 0.0003$), and unacceptable quality of implant placement ($P = 0.006$) were associated with an increased risk of CS or SHS conversion to THA or HA. Unlike in the original analysis, using an ambulatory aid prefracture ($P = 0.04$) was also found to be associated with an increased risk of CS or SHS conversion to THA or HA.

Our study has numerous notable strengths. A total of 1079 patients from 81 clinical sites in the United States, Canada, Australia, the Netherlands, Norway, Germany, the United Kingdom, and India were included in the FAITH trial. The large sample size and diversity of the participants included in the trial increases the external validity and generalizability of our research findings from this analysis. The 7 postsurgery follow-up visits across a 24-month period allowed for frequent and long-term assessment of participant outcomes and all revision surgery events were centrally adjudicated. Additionally, the use of a multivariable Cox proportional hazards regression for our analysis was advantageous, as this type of model helps control for numerous potentially confounding variables when the sample size is large enough.²⁰ Although this study had several strengths, important limitations do exist. Although 1079 patients were included in the primary analysis of the FAITH trial, it was not possible to include them all in this analysis, due to missing data. Also, it may be possible that not all factors associated with revision surgery were collected as part of the FAITH trial. Bone density determination is one important factor in this regard. Only variables collected as part of the FAITH trial could be used in our analysis.

Identifying factors associated with revision surgery will help to optimize the care of hip fracture patients. Understanding which patients are at risk for revision surgery, and specifically which type of revision surgery, can let surgeons communicate these risks to patients when explaining treatment options and

prognosis. Additionally, the variables identified in our analysis may allow for surgeons to consider alternate care options, such as joint replacement, for patients who are at higher risk of revision surgery. Finally, the results of this study may also inform future research by identifying high-risk patients who may benefit from novel interventions and adjuncts to care.

Acknowledgments

FAITH Investigators

Steering Committee: M.B. (Chair, McMaster University), M.S. (University of Minnesota), PJ Devereaux (McMaster University), Gordon Guyatt (McMaster University), Martin J. Heetveld (Spaarne Gasthuis, Haarlem), K.J.J. (Greenville Health System), S.L. (The Alfred), Martin Richardson (University of Melbourne), E.H.S. (University of Western Ontario), Lehana Thabane (McMaster University), Paul Tornetta III (Boston University Medical Center), and Stephen D. Walter (McMaster University).

Global Methods Centre: M.B. (Principal Investigator);

S.S. (Research Methodologist); Paula McKay (Manager); Taryn Scott, Alisha Garibaldi, Helena Viveiros, Marilyn Swinton, (Research Coordination); Mark Gichuru, S.B. (Adjudication Coordination); D.H., Q.Z. (Statistical Analysis); Lisa Buckingham, Aravin Duraikannan (Data Management); Deborah Maddock, Nicole Simunovic (Grants Management) (McMaster University).

United States Methods Centre: M.S. (Principal Investigator); Julie Agel (Research Coordination) (University of Minnesota).

Netherlands Method Centre: Martin J. Heetveld (Principal Investigator); Esther

•

M.M. Van Lieshout (Research Coordination); Stephanie M. Zielinski (Trial Coordination) (Erasmus MC, University Medical Center Rotterdam).

United Kingdom Method Centre: Amar Rangan (Principal Investigator), Birgit C. Hanusch, Lucksy Kottam, Rachel Clarkson (Research Coordination) (The James Cook University Hospital).

Adjudication Committee: G.J.D. (Chair) (Duke University), Robert Haverlag (Onze Lieve Vrouwe Gasthuis), S.L. (The Alfred), G.P.S. (University of Maryland, Baltimore), K.J.J. (Greenville Health System).

Participating Clinical Sites

Canada: Robert McCormack, Kelly Apostle, Dory Boyer, Farhad Moola, Bertrand Perey, Trevor Stone, Darius Viskontas, H. Michael Lemke, Mauri Zomar, Karyn Moon, Raely Moon, Amber Oatt (Royal Columbian Hospital/Fraser Health Authority/University of British Columbia); Richard E. Buckley, Paul Duffy, Robert Korley, Shannon Puloski, James Powell, Kelly Johnston, Kimberly Carcary, Melissa Lorenzo, Ross McKercher (Foothills Medical Centre); David Sanders, Mark MacLeod, Abdel-Rahman Lawendy, Christina Tieszer (London Health Sciences Centre); David Stephen, Hans Kreder, Richard Jenkinson, Markku Nousiainen, Terry Axelrod, John Murnaghan, Diane Nam, Veronica Wadey, Albert Yee, Katrine Milner, Monica Kunz, Wesley Ghent (Sunnybrook Health Sciences Centre); E.H.S., Michael D. McKee, Jeremy A. Hall, Aaron Nauth, Henry Ahn, Daniel B. Whelan, Milena R. Vicente, Lisa M. Wild, Ryan M. Khan, Jennifer T. Hidy (St. Michael's Hospital); Chad Coles, Ross Leighton, Michael Biddulph, David Johnston, Mark Glazebrook, David Alexander, Catherine Coady, Michael Dunbar, J. David Amirault, Michael Gross, William Oxner, Gerald Reardon, C. Glen Richardson, J. Andrew Trenholm, Ivan Wong, Kelly Trask, Shelley

MacDonald, Gwendolyn Dobbin (Queen Elizabeth II Health Sciences Centre); Ryan Bicknell, Jeff Yach, Davide Bardana, Gavin Wood, Mark Harrison, David Yen, Sue Lambert, Fiona Howells, Angela Ward (Human Mobility Research Centre, Queen's University and Kingston General Hospital); Paul Zalzal, Heather Brien, V. Naumetz, Brad Weening, Nicole Simunovic (Oakville Trafalgar Memorial Hospital); Eugene K. Wai, Steve Papp, Wade T. Gofton, Allen Liew, Stephen P. Kingwell, Garth Johnson, Joseph O'Neil, Darren M. Roffey, Vivian Borsella (The Ottawa Hospital); Victoria Avram (Juravinski Hospital and Cancer Centre).

United States: Todd M. Oliver, Vicki Jones, Michelle Vogt (Boone Hospital Center – Columbia Orthopaedic Group); Clifford B. Jones, James R. Ringler, Terrence J. Endres, Debra L. Sietsema, Jane E. Walker (Orthopaedic Associates of Michigan); K.J.J., J. Scott Broderick, David R. Goetz, Thomas B. Pace, Thomas M. Schaller, Scott E. Porter, Michael L. Beckish, John D. Adams, Benjamin B. Barden, Aaron T. Creek, Stephen H. Finley, Jonathan L. Foret, Garland K. Gudger Jr, Richard W. Gurich Jr, Austin D. Hill, Steven M. Hollenbeck, Lyle T. Jackson, Kevin K. Kruse, III, Wesley G. Lackey, Justin W. Langan, Julia Lee, Lauren C. Leffler, Timothy J. Miller, R. Lee Murphy, Jr., Lawrence K. O'Malley II, Melissa E. Peters, Dustin M. Price, John A. Tanksley, Jr., Erick T. Torres, Dylan J. Watson, Scott T. Watson, Stephanie L. Tanner, Rebecca G. Snider, Lauren A. Nastoff, Shea A. Bielby, Robert J. Teasdall (Greenville Health System); Julie A. Switzer, Peter A. Cole, Sarah A. Anderson, Paul M. Lafferty, Mengnai Li, Thuan V. Ly, Scott B. Marston, Amy L. Foley, Sandy Vang, David M. Wright (Regions Hospital-University of Minnesota); Andrew J. Marcantonio, Michael S.H. Kain, Richard Iorio, Lawrence M. Specht, John F. Tilzey, Margaret J. Lobo, John S. Garfi (Lahey Hospital & Medical Center); Heather A. Vallier, Andrea Dolenc,

.

Mary Breslin (MetroHealth Medical Center); Michael J. Prayson, Richard Laughlin, L. Joseph Rubino, Jedediah May, Geoffrey Ryan Rieser, Liz Dulaney-Cripe, Chris Gayton (Miami Valley Hospital); James Shaer, Tyson Schrickel, Barbara Hileman (St. Elizabeth Youngstown Hospital); John T. Gorczyca, Jonathan M. Gross, Catherine A. Humphrey, Stephen Kates, John P. Ketz, Krista Noble, Allison W. McIntyre, Kaili Pecorella (University of Rochester Medical Center); Craig A. Davis, Stuart Weinerman, Peter Weingarten, Philip Stull, Stephen Lindenbaum, Michael Hewitt, John Schwappach, Janell K. Baker, Tori Rutherford, Heike Newman, Shane Lieberman, Erin Finn, Kristin Robbins, Meghan Hurley, Lindsey Lyle, Khalis Mitchell, Kieran Browner, Erica Whatley, Krystal Payton, Christina Reeves (Colorado Orthopedic Consultants); Lisa K. Cannada, David E. Karges, Sarah A. Dawson (St. Louis University Hospital); Samir Mehta, John Esterhai, Jaimo Ahn, Derek Donegan, Annamarie D. Horan, Patrick J. Hesketh, Evan R. Bannister (University of Pennsylvania); Jonathan P. Keeve, Christopher G. Anderson, Michael D. McDonald, Jodi M. Hoffman (Northwest Orthopaedic Specialists); Ivan Tarkin, Peter Siska, Gary Gruen, Andrew Evans, Dana J. Farrell, James Irrgang, Arlene Luther (University of Pittsburgh Medical Center); William W. Cross III, Joseph R. Cass, Stephen A. Sems, Michael E. Torchia, Tyson Scrabeck (Mayo Clinic); Mark Jenkins, Jules Dumais, Amanda W. Romero (Texas Tech University Health Sciences Center – Lubbock); Carlos A. Sagebien, Mark S. Butler, James T. Monica, Patricia Seuffert (University Orthopaedic Associates, LLC); Joseph R. Hsu, Daniel Stinner, James Ficke, Michael Charlton, Matthew Napierala, Mary Fan (US Army Institute of Surgical Research); Paul Tornetta III, Chadi Tannoury, Hope Carlisle, Heather Silva (Boston University Medical Center); Michael Archdeacon, Ryan Finnan, Toan Le, John Wyrick, Shelley Hess (UC Health/University of Cincinnati Medical Center); Michael L. Brennan, Robert Probe, Evelyn Kile, Kelli Mills, Lydia

•

Clipper, Michelle Yu, Katie Erwin (Scott and White Memorial Hospital); Daniel Horwitz, Kent Strohecker, Teresa K. Swenson (Geisinger Medical Center); Andrew H. Schmidt, Jerald R. Westberg (Hennepin County Medical Center); Kamran Aurang, Gary Zohman, Brett Peterson, Roger B. Huff (Kaiser Permanente); Joseph Baele, Timothy Weber, Matt Edison (OrthoIndy Trauma St. Vincent Trauma Center); Jessica Cooper McBeth (Santa Clara Valley Medical Center); Karl Shively, Janos P. Ertl, Brian Mullis, J. Andrew Parr, Ripley Worman, Valda Frizzell, Molly M. Moore (Indiana University—Eskenazi Health Services); Charles J. DePaolo, Rachel Alosky, Leslie E. Shell, Lynne Hampton, Stephanie Shepard, Tracy Nanney, Claudine Cuento (Mission Hospital Research Institute); Robert V. Cantu, Eric R. Henderson, Linda S. Eickhoff (Dartmouth-Hitchcock Medical Center); E. Mark Hammerberg, Philip Stahel, David Hak, Cyril Mauffrey, Corey Henderson, Hannah Gissel, Douglas Gibula (Denver Health and Hospital Authority); David P. Zamorano, Martin C. Tynan, Deeba Pourmand, Deanna Lawson (University of California Irvine Medical Center); G.J.D., Brett D. Crist, Yvonne M. Murtha, Linda K. Anderson (University of Missouri Health Care); Colleen Linehan, Lindsey Pilling (Covenant Healthcare of Saginaw); Courtland G. Lewis, Stephanie Caminiti, Raymond J. Sullivan, Elizabeth Roper (Hartford Hospital); William Obremskey, Philip Kregor, Justin E. Richards, Kenya Stringfellow (Vanderbilt University Medical Center); Michael P. Dohm, Abby Zellar (Western Slope Study Group).

The Netherlands: Michiel J.M. Segers, Jacco A.C. Zijl, Bart Verhoeven, Anke B. Smits, Jean Paul P.M. de Vries, Bram Fioole, Henk van der Hoeven, Evert B.M. Theunissen, Tammo S. de Vries Reilingh, Lonneke Govaert, Philippe Wittich, Maurits de Brauw, Jan Wille, Peter M.N.Y.M. Go, Ewan D. Ritchie, Ronald N. Wessel, Eric R. Hammacher (St. Antonius Ziekenhuis); Martin J. Heetveld, Gijs A.

•

Visser, Heyn Stockmann, Rob Silvis, Jaap P. Snellen, Bram Rijbroek, Joris J.G. Scheepers, Erik G.J. Vermeulen, Michiel P.C. Siroen, Ronald Vuylsteke, Hans L.F. Brom, Herman Rijna (Kennemer Gasthuis); Piet A.R. de Rijcke, Cees L. Koppert, Steven E. Buijk, Richard P.R. Groenendijk, Imro Dawson, Geert W.M. Tetteroo, Milko M.M. Bruijninx, Pascal G. Doornebosch, Eelco J.R. de Graaf (IJsselland Ziekenhuis); Maarten van der Elst, Carmen C. van der Pol, Martijne van 't Riet, Tom M. Karsten, Mark R. de Vries, Laurents P.S. Stassen, Niels W.L. Schep, G. Ben Schmidt, W.H. Hoffman (Reinier de Graaf Gasthuis); Rudolf W. Poolman, Maarten P. Simons, Frank H.W.M. van der Heijden, W. Jaap Willems, Frank R.A.J. de Meulemeester, Cor P. van der Hart, Kahn Turckan, Sebastiaan Festen, Frank de Nies, Robert Haverlag, Nico J.M. Out, Jan Bosma (Onze Lieve Vrouwe Gasthuis); Albert van Kampen, Jan Biert, Arie B. van Vugt, Michael J.R. Edwards, Taco J. Blokhuis, Jan Paul M. Frölke, Leo M.G. Geeraedts, Jean W.M. Gardeniers, Edward C.T.H. Tan, Lodewijk M.S.J. Poelhekke, Maarten C. de Waal Malefijt, Bart Schreurs (University Medical Center St. Radboud); Gert R. Roukema, Hong A. Josaputra, Paul Keller, Peter D. de Rooij, Hans Kuiken, Han Boxma, Berry I. Cleffken, Ronald Liem (Maasstad Ziekenhuis); Steven J. Rhemrev, Coks H.R. Bosman, Alexander de Mol van Otterloo, Jochem Hoogendoorn, Alexander C. de Vries, Sven A.G. Meylaerts (Medisch Centrum Haaglanden); Michiel H.J. Verhofstad, Joost Meijer, Teun van Egmond, Frank H.W.M. van der Heijden, Igor van der Brand (St. Elisabeth Ziekenhuis); Peter Patka, Martin G. Eversdijk, Rolf Peters, Dennis Den Hartog, Oscar J.F. Van Waes, Pim Oprel (Erasmus MC, University Medical Center Rotterdam); Harm M van der Vis, Martin Campo, Ronald Verhagen, G.H. Robert Albers, Arthur W. Zurcher (Tergooi Ziekenhuizen); Rogier K.J. Simmermacher, Jeroen van Mulken, Karlijn van Wessem, Taco J. Blokhuis, Steven M. van Gaalen, Luke P.H. Leenen (University Medical Center Utrecht); Maarten W.G.A. Bronkhorst, Onno R.

Guicherit (Bronovo Ziekenhuis); J. Carel Goslings, Robert Haverlag, Kees Jan Ponsen (Academic Medical Center).

International: Mahesh Bhatia, Vinod Arora, Vivek Tyagi (RLB Hospital and Research Centre, India); S.L., Harvinder Bedi, Ashley Carr, Hamish Curry, Andrew Chia, Steve Csongvay, Craig Donohue, Stephen Doig, Elton Edwards, Greg Etherington, Max Esser, Andrew Gong, Arvind Jain, Doug Li, Russell Miller, Ash Moaveni, Matthias Russ, Lu Ton, Otis Wang, Adam Dowrick, Zoe Murdoch, Claire Sage (The Alfred, Australia); Frede Frihagen, John Clarke-Jenssen, Geir Hjorthaug, Torben Ianssen, Asgeir Amundsen, Jan Egil Brattgjerd, Tor Borch, Berthe Bøe, Bernhard Flatøy, Sondre Hasselund, Knut Jørgen Haug, Kim Hemlock, Tor Magne Hoseth, Geir Jomaas, Thomas Kibsgård, Tarjei Lona, Gilbert Moatshe, Oliver Müller, Marius Molund, Tor Nicolaisen, Fredrik Nilsen, Jonas Rydinge, Morten Smedsrud, Are Stødle, Axel Trommer, Stein Ugland, Anders Karlsten, Guri Ekås, Elise Berg Vesterhus, Anne Christine Brekke (Oslo University Hospital, Norway); Ajay Gupta, Neeraj Jain, Farah Khan (Nirmal Hospital, India); Ateet Sharma, Amir Sanghavi, Mittal Trivedi (Satellite Orthopaedic Hospital and Research Centre, India); Anil Rai, Subash, Kamal Rai (Highway Hospital, India); Vineet Yadav, Sanjay Singh, Kamal Rai (Popular Hospital, India); Kevin Tetsworth, Geoff Donald, Patrick Weinrauch, Paul Pincus, Steven Yang, Brett Halliday, Trevor Gervais, Michael Holt, Annette Flynn (Royal Brisbane and Women's Hospital, Australia); Amal Shankar Prasad, Vimlesh Mishra (Madhuraj Nursing Home, India); D.C. Sundaresh, Angshuman Khanna (M.S. Rammaiah Medical College & Hospital, India); Joe Joseph Cherian, Davy J Olakkengil, Gaurav Sharma (St John's Medical College Hospital, India); Marinis Pirpiris, David Love, Andrew Bucknill, Richard J Farrugia (Royal Melbourne Hospital, Australia); Hans-Christoph Pape, Matthias Knobe, Roman Pfeifer

.

(University of Aachen Medical Center, Germany); Peter Hull, Sophie Lewis, Simone Evans (Cambridge University Hospitals, England); Rajesh Nanda, Rajanikanth Logishetty, Sanjeev Anand, Carol Bowler (University Hospital of North Tees, England); Akhil Dadi, Naveen Palla, Utsav Ganguly (Sunshine Hospital, India); B. Sachidananda Rai, Janakiraman Rajakumar (Unity Health Complex, India); Andrew Jennings, Graham Chuter, Glynis Rose, Gillian Horner (University Hospital of North Durham and Darlington Memorial Hospital, England); Callum Clark, Kate Eke (Wexham Park Hospital, England); Mike Reed, Dominic Inman, Chris Herriott, Christine Dobb (Northumbria Healthcare NHS Foundation Trust, England).

References

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int*. 2006;17:1726–1733.
2. Florschutz AV, Langford JR, Haidukewych GJ, et al. Femoral neck fractures: current management. *J Orthop Trauma*. 2015;29:121–129.
3. Kurtinaitis J, Porvaneckas N, Kvederas G, et al. Revision rates after surgical treatment for femoral neck fractures: results of 2-year follow-up. *Med Kaunas*. 2013;49:138–142.
4. Lin JC, Liang WM. Outcomes after fixation for undisplaced femoral neck fracture compared to hemiarthroplasty for displaced femoral neck fracture among the elderly. *BMC Musculoskelet Disord*. 2015;16:199.
5. Parker MJ, Gurusamy K. Internal fixation versus arthroplasty for intracapsular proximal femoral fractures in adults. *Cochrane Database Syst Rev*. 2006:CD001708.
6. Bhandari M, Tornetta P III, Hanson B, et al. Optimal internal fixation for femoral neck fractures: multiple screws or sliding hip screws? *J Orthop Trauma*. 2009;23:403–407.
7. Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) Investigators. Fracture fixation in the operative management of hip fractures (FAITH): an international, multicentre, randomised controlled trial. *Lancet*. 2017;389:1519–1527.
8. Investigators FAITH. Fixation using alternative implants for the treatment of hip fractures (FAITH): design and rationale for a multi-centre randomized trial comparing sliding hip screws and cancellous screws on revision surgery rates and quality of life in the treatment of femoral neck fractures. *BMC Musculoskelet Disord*. 2014;15:219.

9. Gregersen M, Krogshede A, Brink O, et al. Prediction of reoperation of femoral neck fractures treated with cannulated screws in elderly patients. *Geriatr Orthop Surg Rehabil*. 2015;6:322–327.
10. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol*. 1996;49:1373–1379.
11. Patel RA, Wilson RF, Patel PA, et al. The effect of smoking on bone healing: a systematic review. *Bone Jt Res*. 2013;2:102–111.
12. Zhu Y, Liu S, Zhang X, et al. Incidence and risks for surgical site infection after adult tibial plateau fractures treated by ORIF: a prospective multicentre study. *Int Wound J*. 2017;14:982–988.
13. Scolaro JA, Schenker ML, Yannascoli S, et al. Cigarette smoking increases complications following fracture: a systematic review. *J Bone Jt Surg Am*. 2014;96:674–681.
14. Castillo RC, Bosse MJ, MacKenzie EJ, et al. Impact of smoking on fracture healing and risk of complications in limb-threatening open tibia fractures. *J Orthop Trauma*. 2005;19:151–157.
15. Abate M, Vanni D, Pantalone A, et al. Cigarette smoking and musculoskeletal disorders. *Muscles Ligaments Tendons J*. 2013;3:63–69.
16. van Embden D, Roukema GR, Rhemrev SJ, et al. The Pauwels classification for intracapsular hip fractures: is it reliable? *Injury*. 2011;42:1238–1240.
17. Lindequist S, Törnkvist H. Quality of reduction and cortical screw support in femoral neck fractures. An analysis of 72 fractures with a new computerized measuring method. *J Orthop Trauma*. 1995;9: 215–221.
18. Hoelsbrekken SE, Opsahl JH, Stiris M, et al. Failed internal fixation of femoral neck fractures. *Tidsskr Nor Laegeforen*. 2012;132:1343–1347.
19. Yu L, Wang Y, Chen J. Total hip arthroplasty versus hemiarthroplasty for

-
- displaced femoral neck fractures: meta-analysis of randomized trials. Clin Orthop Relat Res. 2012; 470:2235–2243.
20. Hajian Tilaki K. Methodological issues of confounding in analytical epidemiologic studies. Casp J Intern Med. 2012;3:488–495.

TABLE 1. Factors Associated With Revision Surgery (n = 815; 191 Events)

Independent Variable	Hazard Ratio (95% confidence interval)	P
Gender		
Female versus Male	1.79 (1.25–2.50)	0.001
Body mass index (Change in 5 points)	1.19 (1.02–1.39)	0.027
Fracture displacement		
Displaced versus undisplaced	2.16 (1.44–3.23)	0.0002
Pauwels classification		
Type I versus type III	0.54 (0.26–1.15)	0.11
Type III versus type II	2.13 (1.28–3.57)	0.004
Quality of implant placement		
Unacceptable versus acceptable; (Acceptable, n = 776; Unacceptable, n = 39)	2.70 (1.59–4.55)	0.0002
Interaction		0.01
Smoking status		
Current versus other (nonsmokers/previous smokers) for Cancellous screws	1.89 (1.10–3.25)	0.021
Current versus other for sliding hip screw	0.62 (0.32–1.21)	0.16
Treatment		
Cancellous screws versus sliding hip screw for current smokers	2.94 (1.35–6.25)	0.006
Sliding hip screw versus cancellous screws for other (nonsmokers/previous smokers)	1.05 (0.75–1.47)	0.77
Age (Change in 10 y)	1.05 (0.87–1.26)	0.62
ASA Classification		
Class II versus class I	0.76 (0.48–1.2)	0.24
Class III versus class I	0.84 (0.45–1.55)	0.57
Class IV versus class I	0.22 (0.04–1.1)	0.06
Class V versus class I	No data	
Pre-fracture living setting		
Institutionalized versus Not institutionalized	0.97 (0.33–2.79)	0.95
Prefracture functional status		
Using ambulatory aid versus independent ambulator	1.47 (0.92–2.37)	0.11
Diabetes		
Yes versus No	0.87 (0.54–1.38)	0.55
Level of the fracture line		
Midcervical versus subcapital	0.73 (0.47–1.14)	0.16
Basal versus subcapital	0.55 (0.23–1.30)	0.17
Type of reduction		
None versus open	0.82 (0.32–2.07)	0.67
Closed versus open	1.10 (0.43–2.79)	0.85
Time from injury to surgery (d)	1 (0.95–1.06)	0.88

TABLE 2. Factors Associated With Hardware Removal (n = 894; 70 Events)

Variable	Hazard Ratio (95% confidence interval)	<i>P</i>
Age (Change in 10 y)	1.39 (1.05–1.85)	0.020
Fracture displacement		
Displaced versus undisplaced	2.91 (1.63–5.18)	0.0003
Quality of implant placement		
Unacceptable versus acceptable	2.56 (1.11–5.88)	0.027
Interaction		0.02
Smoking status		
Current versus other (nonsmokers/ previous smokers) for cancellous screws	2.03 (0.91–4.51)	0.12
Current versus other for sliding hip screw	0.35 (0.10–1.30)	0.08
Treatment		
Sliding hip screw versus cancellous screws for current smokers	0.09 (0.02–0.37)	0.001
Sliding hip screw versus cancellous screws for other (nonsmokers/ previous smokers)	0.53 (0.29–0.96)	0.04
Body mass index (Change in 5 points)	1.03 (0.75–1.41)	0.86
Prefracture functional status		
Using ambulatory aid versus independent ambulator	0.62 (0.21–1.83)	0.39

TABLE 3. Factors Associated With Implant Exchange (n = 823; 143 Events)

Variable	Hazard Ratio (95% confidence interval)	P
Gender		
Female versus male	2.00 (1.32–3.03)	0.001
Fracture displacement		
Displaced versus undisplaced	2.31 (1.45–3.69)	0.0005
Quality of implant placement: unacceptable versus acceptable. (acceptable, n = 852; unacceptable, n = 42)	2.38 (1.32–4.35)	0.0004
Age (change in 10 y)	1.14 (0.94–1.39)	0.17
Prefracture functional status		
Using ambulatory aid versus independent ambulator	1.54 (0.96–2.46)	0.07
Diabetes		
Yes versus no	1.00 (0.60–1.64)	0.99
Level of the fracture line		
Midcervical versus subcapital	0.83 (0.54–1.26)	0.37
Basal versus subcapital	0.85 (0.34–2.16)	0.73
Type of reduction		
None versus open	1.3 (0.4–4.21)	0.66
Closed versus open	1.71 (0.52–5.59)	0.38
Time from injury to surgery (d)	0.99 (0.93–1.06)	0.76
Interaction		0.07
Smoking status		
Current versus other (nonsmokers/ previous smokers) for cancellous screws	1.39 (0.72–2.69)	0.33
Current versus other for sliding hip screw	0.58 (0.28–1.21)	0.14
Treatment		
Sliding hip screw versus cancellous screws for current smokers	0.52 (0.22–1.24)	0.14
Sliding hip screw versus cancellous screws for other (nonsmokers/previous smokers)	1.25 (0.86–1.83)	0.25